GI Pancreatic - Metastatic

First Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB# 22619: A Phase II Trial of Preoperative Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula following Distal Pancreatectomy

Second Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB# 24213: Polyglycolic Acid Mesh to Prevent Pancreatic Fistula After Distal Pancreatectomy: A Multi-Center Efficacy Trial

Third Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB# 17094: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Localized

- NeoAdjuvant
- Adjuvant

Adjuvant

- IRB# 19211: A Feasibility Study to Assess a Window of Opportunity Strategy for Targeted PARP or MEK Inhibition in Patients with Pancreatic Ductal Adenocarcinoma
- IRB# 21614: NeoOptimize: An Open-Label, Phase II Trial To Assess The Efficacy Of Adaptive Switching Of mFolfirinox Or Gemcitabine/Nab-Paclitaxel As A NeoAdjuvant Strategy For Patients With Resectable And Borderline Resectable Pancreatic Cancer.
- IRB# 17751: Trans(Intra-)arterial Gemcitabine vs. Continuation of IV Gemcitabine and Nab-Paclitaxel following Radiotherapy for Locally Advanced Pancreatic Cancer
- IRB# 15588: New study will be available soon.

First Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB# 17094: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

- IRB# 23316: A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumours

- IRB# 23124: A Phase Ib/2 Randomized Study of AVB-S6-500 plus Nab-Paclitaxel and Gemcitabine in Patients with Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma

Cross-Disease Trials:

- IRB# 17094: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
- IRB# 17094: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

http://www.ohsu.edu/research/rda/so/knight.php